Download presentation
Presentation is loading. Please wait.
Published byClara Veenstra Modified over 6 years ago
1
Expansion of cytotoxic CD56bright natural killer cells during T-cell deficiency after allogeneic hematopoietic stem cell transplantation Gertjan Lugthart, MD, Marieke Goedhart, MSc, Merle M. van Leeuwen, MSc, Janine E. Melsen, MSc, Cornelia M. Jol-van der Zijde, Carly Vervat, Monique M. van Ostaijen-ten Dam, Anja M. Jansen-Hoogendijk, Maarten J.D. van Tol, PhD, Arjan C. Lankester, MD, PhD, Marco W. Schilham, PhD Journal of Allergy and Clinical Immunology Volume 140, Issue 5, Pages (November 2017) DOI: /j.jaci Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions
2
Fig 1 Expansion of CD56bright NK cells in patients with delayed T-cell reconstitution. A-C, Reconstitution of T cells (Fig 1, A), CD56bright cells (Fig 1, B), and CD56dim NK cells (Fig 1, C) in 93 HSCT recipients. Each row represents a patient. Patients were sorted by T-cell reconstitution. HD values are shown in the legend. D, Side bars displaying donor type, graft source, graft versus host (GvHD) prophylaxis, and active (T-cell binding) ATG concentration. AU, Arbitrary units; BM, bone marrow; CSA, cyclosporin A; IRD, identical related donor; MMF, mycophenolate mofetil; MTX, methotrexate; MUD, matched unrelated donor. Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions
3
Fig 2 Phenotype and function of CD56bright NK cells after HSCT. A and B, t-SNE analysis of the expression of 34 cell-surface markers on CD56bright NK cells in 134 samples from 20 HSCT recipients and 16 HDs. Distance between dots indicates the difference in phenotype. Plots are colored by time after HSCT (Fig 2, A) and marker expression (Fig 2, B). Range: percentage or fluorescence-intensity (FI). For gating strategy and nondepicted markers, see this article's Online Repository at C and D, Intracellular expression of granzyme B and perforin in NK cells at 4, 12, and 52 weeks after HSCT (n = 3) and in HDs (n = 3). Bars: mean ± SEM. E, Cytotoxicity of unmanipulated PBMCs 3 and 10 weeks after HSCT and in HDs (week 3, >95% CD56bright). F, Resting and overnight IL-15–activated FACS-purified HD NK cells. Representative graphs of 3 (Fig 2, E) and 2 (Fig 2, F) experiments. Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions
4
Fig E1 Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions
5
Fig E2 Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions
6
Fig E3 Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions
7
Fig E4 Journal of Allergy and Clinical Immunology , DOI: ( /j.jaci ) Copyright © 2017 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.